

ESMO Clinical Practice Guidelines

DLBCL Case Discussion

Michael Pfreundschuh

German High Grade Non-Hodgkin's Lymphoma
Study Group

Saarland University Medical School
Homburg (Saar), Germany

Disclosures

No potential conflicts of interest declared

ESMO Guidelines DLBCL 2012

Diagnosis of DLBCL:

- **Excisional biopsy of involved lymph node / extralymphatic tissue**
- **Diagnosis made by experience hematopathologist**
- **Morphology**
- **Immunohistochemistry**
- **Gene expression profiling: research tool (poor standardization)**
- **Immunohistochemical algorithms for the distinction of germinal center from non-germinal center (ABC-) subtype not reproducible**
- **No differential therapy established**

ESMO Guidelines DLBCL 2012

Prognostication and therapeutic strategy for DLBCL:

- IPI valid in the rituximab era
- LDH
- Age >60 years
- Advanced stage
- >1 extralymphatic site of involvement
- ECOG performance status >1

ESMO Guidelines DLBCL 2012

Prognostication and therapeutic strategy for DLBCL:

- IPI valid in the rituximab era

LDH ✓

Age >60 years ✓

Advanced stage ✓

>1 extralymphatic site of involvement ✓

ECOG performance status >1 ?

- Patient:

IPI=4 (high risk group)

ESMO Guidelines DLBCL 2012

Recommended treatments for elderly DLBCL:

- 8xR-CHOP-21(6xR-CHOP-21, if in CR after 4 cycles)
- 6xR-CHOP-14 + 2R
- Interim PET not recommended
- No recommendation with respect to additive radiotherapy to bulky disease in elderly patients

ESMO Guidelines DLBCL 2012

Recommendations for relapsed/refractory DLBCL:


- Platinum-containing regimen for re-induction
- R-DHAP might be better than R-ICE in GC-DLBCL
- Responding patients should receive HD-ChT + ASCT
- Prior rituximab + duration of CR <12 months: poor prognosis
- Allogeneic SCT may be considered for:
 - failure after ASCT
 - poor risk factors at relapse

High-Dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation in High-Risk Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma: Results of a Prospective Study of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL-R3)


A graphic element on the left side of the slide features three stylized, overlapping silhouettes of medical professionals. One figure is orange, one is red, and one is green. Each figure is wearing a white coat and a stethoscope around their neck. They appear to be in a discussion or a team meeting.



Bertram Glass, Justin Hasenkamp, Gerald Wulf, Peter Dreger, Michael Pfreundschat, Martin Gramatzki, Gerda Silling, Christian Wilhelm, Matthias Zeis, Anke Görlitz, Lorenz Trümper and Norbert Schmitz



on behalf of the German High-Grade Lymphoma Study Group (DSHNHL)




CORAL-Study Failure from diagnosis < 12 months









Einschlusskriterien:

Aggressives NHL, B oder T-NHL

Alter > 18 Jahre